2m 2m 2m 2m 2m 2m 2m
Halozyme Therape (HALO)
NASDAQ
$69.35+$0.36 (+0.52%)
Price as of Jun 23, 2026 3:27 PM EDT- $8.2BMarket Cap
- 30.66%1-Year Change
- BiotechnologyIndustry
Halozyme Therape (HALO)
$69.35+$0.36 (+0.52%)
HALO | vs History | vs S&P 500 | |
|---|---|---|---|
General Statistics | |||
Latest Close | $68.99 | ||
Change | +$0.44 (+0.64%) | ||
Open | $69.34 | ||
High | $69.81 | ||
Low | $68.27 | ||
Previous Close | $68.55 | ||
Volume | 1,054,256 | ||
30-Day Average Volume | 1,821,799 | ||
1-Week Change | -3.21% | ||
1-Month Change | 0.98% | ||
1-Year Change | 30.66% | ||
3-Year Change | 94.72% | ||
5-Year Change | 60.26% | ||
Fundamentals | |||
Shares Outstanding | 118.6M | ||
Total Assets | $2.7B | ||
Market Cap | $8.2B | ||
Enterprise Value | $10.0B | ||
Period: QTR TTM FY | |||
Revenue | $240.7M | ||
Net Income | $150.0M | ||
Free Cash Flow | $176.3M | ||
EBIT | $180.7M | ||
EBITDA | $210.2M | ||
Net Working Capital | $639.8M | ||
EPS | $1.22 | ||
Enterprise Value/EBITDA | 48 | ||
Enterprise Value/Revenue | 42 | ||
P/B | 37 | ||
P/E | 57 | ||
PEG | 0 | ||
Price/Free Cash Flow | 46 | ||
Price/Operating Cash Flow | 45 | ||
Dividends & Splits | |||
Forward Annual Dividend Yield | N/A | ||
Trailing Annual Dividend Yield | N/A | ||
Ex-Dividend Date | N/A | ||
Last Split Factor | N/A | ||
Last Split Date | N/A | ||
Earnings & Revenue